The Effect of Inactivated SARS-CoV-۲ Vaccinationon Assis ted Reproductive Technology (ART) Outcomes inRoyan Ins titute

Background: According to the World Health Organization advice,the only way to control COVID-۱۹ pandemic is to get thevaccination and follow health tip. People vaccinated by the inactivatedvaccine mos tly in Iran. This s tudy is about evaluatingthe relationship between inactivated SARS-CoV-۲ vaccinationand ART outcomes.Materials and Methods: In this observational before afterclinical s tudy, all couples who undergoing consecutive ovarians timulation for ART cycle before and after the second dose ofthe vaccines were approached to participate in the s tudy (fromJune ۲۰۲۱ until February ۲۰۲۲). The patients with followingcharacteris tics were excluded from the s tudy: women olderthan ۴۰, men with a severe male factor reason, need for preimplantationgenetic diagnosis, an underlying disease, his toryof covid-۱۹ infection, BMI>۳۰, donor egg and embryo.Results: ۳۱ eligible couples have participated in this s tudy. Accordingto our defined inclusion criteria ۲۹ of them were vaccinatedby Sinopharm vaccine and the other ۳ were vaccinated byBarekat. The approximate period between their ۲ shots of vaccinationwas about ۲۶۲ ± ۲۷ days. The mean interval betweenthe second vaccination time and date of OPU (Ovum Pick Up)was ۷۵ ± ۵ days. Different results of the ART cycle were notsignificantly different before and after vaccination, the numberof antral follicle count (۹.۳۸ ± ۵.۸۳ vs. ۹.۲۵ ± ۵.۸۲), number ofretrieved oocytes (۵.۳۷ ± ۴.۱۸ vs. ۶.۲۴ ± ۴.۵۷), number of immatureoocytes (۱.۱۶ ± ۲.۰۷ vs. ۱.۴۵ ± ۲.۳۶), number of matureoocytes (۴.۳۵ ± ۲.۹۸ vs. ۵.۱۹±۴.۳۲), number of ۲PN (۳.۰۶ ±۲.۴۶ vs. ۳.۸۷ ± ۳.۱۴), and number of embryos (۲.۹۳ ± ۲.۶۲ vs.۳.۹۳ ± ۳.۲۰).Conclusion: Covid-۱۹ vaccination has no negative effect onART cycle outcomes. More several s tudies with longer followupsare highly needed to confirm our observation in future.

کلیدواژه ها:

Assis ted Reproductive Technology ، Covid-۱۹ Vaccination ، Infertility ، SARS-CoV-۲